Aurora Cannabis, Growing Like a Weed, New Financing and Analysts Opinion


Aurora Cannabis Inc. (OTCQX: ACBFF), through its wholly-owned subsidiary, Aurora Cannabis Enterprises Inc., is a licensed producer of medical cannabis under Health Canada’s Access to Cannabis for Medical Purposes Regulations(“ACMPR”).


Aurora has positioned itself to be one of the most significant suppliers of the growing demand for medical and legal recreational in Canada and other parts of the world. The company

continues to experience increasing patient count, and German exports continue to drive the overall

revenue and margins up.


ACBFF is a huge cannabis enterprise with a market cap over $6 billion. Over the past year in particular, Aurora seems to have connected with, invested in, or acquired most of the significant cannabis companies in Canada. With plenty of cash and credit available, ACBFF may become one of North America’s largest cannabis players.


Aurora received its license to produce and sell medical cannabis on February 17, 2015 and

November 27, 2015, respectively. The Company received its license to produce and sell cannabis oil

products on February 16, 2016 and January 20, 2017, respectively.


The new Canada cannabis law is coming into force on October 17th, 2018, subject to provincial or territorial restrictions, adults who are 18 years of age or older would be able legally to:


  • possess up to 30 grams of legal cannabis, dried or equivalent in non-dried form in public
  • share up to 30 grams of legal cannabis with other adults
  • buy dried or fresh cannabis and cannabis oil from a provincially-licensed retailer

in provinces and territories without a regulated retail framework, individuals would be able to purchase cannabis online from federally-licensed producers

  • grow, from licensed seed or seedlings, up to 4 cannabis plants per residence for personal use
  • make cannabis products, such as food and drinks, at home as long as organic solvents are not used to create concentrated products
  • Cannabis edible products and concentrates will be legal for sale approximately one year after the Cannabis Act has come into force on October 17th, 2018.



Recent Events

September 5, 2018. As part of its ongoing commitment to the arts, Aurora Cannabis announced its support of Share Her Journey, a fundraising campaign organized by the Toronto International Film Festival (TIFF) that prioritizes gender parity while increasing participation, skills, and opportunities for women behind and in front of the camera. Aurora has already made a significant contribution and is working closely with the organizers on additional fundraising opportunities during the festival.


September 4, 2018. Aurora Cannabis announced that it has closed its previously announced debt facility with the Bank of Montreal. The facility consists of a $150 million term loan and a $50 million revolving credit facility, both of which mature in 2021. Included in the facility is an option to upsize the facility to $250 million total following the implementation of Bill C-45 on October 17, 2018, subject to agreement by BMO and satisfaction of certain legal and business conditions.


August 13, 2018. The Company has successfully shipped cultivars from its Mountain facility to Denmark to commence populating the Phase I Aurora Nordic facility, a 100,000 square foot, retrofitted hybrid greenhouse, which will be ramping up to full production capacity of 8,000 kg per year of medical cannabis over the coming months. Aurora Nordic is a 51%-Aurora owned subsidiary owned in partnership with Alfred Pederson & Son.



The Company operates a purpose-built 55,200 square foot production facility based in Mountain View County, Alberta with a current annual capacity of approximately 5,400 kilograms of high quality cannabis. Aurora also has 7.7 million square feet for land available at the Mountain View site for potential future expansion. Alberta is an ideal production location due to low energy, labor and tax costs.

Aurora is currently constructing two additional production facilities in Canada:

  • Edmonton, Alberta: an 800,000 square foot production facility “Aurora Sky” at the Edmonton International Airport
  • Pointe-Claire, Quebec: a 40,000 square foot production facility on Montreal’s West Island.

Aurora also owns Pedanios, a leading wholesale importer, exporter, and distributor of medical cannabis in the European Union (“EU”), based in Germany. In addition, the Company holds approximately 9.6% of the issued shares (12.9% on a fully-diluted basis) in the leading extraction technology company Radient Technologies Inc. (“Radient”), based in Edmonton, and is the cornerstone investor with a 19.9% stake in Cann Group Limited (Cann Group”), the first Australian company licensed to conduct research on, and cultivate, medical cannabis. The company has affiliations or ownership interests in many more companies.

The company has a strategic agreement with Capcium Inc.; and partnership agreement with Evio Beauty Group Ltd., as well as collaborative agreement with McGill University



Aurora Cannabis Inc. produces and distributes medical cannabis products in Canada and internationally. It is vertically integrated and horizontally diversified across every principal segment of the value chain, including facility engineering and design, cannabis breeding and genetics research, cannabis and hemp production, derivatives, value-add product development, home cultivation, wholesale, and retail distribution. The company’s products consist of dried cannabis and cannabis oil. It has a strategic agreement with Capcium Inc.; and partnership agreement with Evio Beauty Group Ltd., as well as collaborative agreement with McGill University. Aurora Cannabis Inc. is headquartered in Vancouver, Canada.



Financial review

Q3 ended March 31, 2018

Revenues                                        $16,100,000

Gross profit                                        7,615,000


Expenses                                         39,371,000


Operating loss                                31,756,000


Net loss                                           20,795,000



Stock influences and risk factors

  • The positive outcome of the upcoming catalyst (as outlined above), would be the key near-term

trigger for the company

  • The key near to medium term drivers would be to the legalization of recreational marijuana in

Canada, further improving its cash position to invest in increasing capacity and any significant

advancement in Germany which would be a significant contributor to profitability and earnings


  • In this sector, the regulatory framework and science are rapidly changing and evolving. Therefore,

new companies are emerging, and regulatory risk always exists for the players in the industry.


Stock chart

On Wednesday, September 5, 2018, ACBFF shares were at $6.66 on traded volume of 5.1 million shares. The current RSI (14) is 58.42

At $6.66, ACBFF shares are trading above their 50 DMA of $5.99 and below their 200 DMA of $7.04.



Traders News Source is a wholly owned subsidiary of Traders News Source LLC, herein referred to as TNS LLC.
Traders News Source has not been compensated for this report by anyone and the opinions if any are that of the author Vikas Agrawal, CFA. Author’s Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I, wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in the article.
This web site, published by TNS LLC, and is an investment newsletter that is built on the premise of assisting individual investors in learning about investing. Our goal as publishers of financial information is to provide research and analysis of investments to our subscribers. TNS LLC does not give buy or sell recommendations. We do purchase distribution rights from analyst, financial writers and bloggers for a fee that may be licensed to issue price targets and recommendations. Furthermore, we encourage you to speak to a licensed professional prior to making an investment in any type of publicly traded security.
We do sell advertising to other companies including brokerage firms, web sites, publicly traded issuers, investor relations firms, and investment publications, among others. TNS LLC makes no warranty as to the policies of these organizations, and in no way endorses their offers, services, or the content of their advertisements.
When an advertiser is a publicly traded company or a third party acting on behalf of a public company, we fully disclose all compensation in the email advertisement. Such disclosure is included in a disclosure statement in each of the advertisements sent via email.
17B Disclosure
Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.
PLEASE NOTE WELL: TNS LLC and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.
Release of Liability: Through use of this website viewing or using you agree to hold TNS LLC, its operator’s owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. TNS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and TNS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead TNS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D.
TNS LLC is compliant with the Can Spam Act of 2003. TNS LLC does not offer such advice or analysis, and TNS LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled.
The Private Securities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions & quote; “may”, “could”, or “might” occur.
Understand there is no guarantee past performance will be indicative of future results. In preparing this publication, TNS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, TNS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. TNS LLC is not responsible for any claims made by the companies advertised herein, nor is TNS LLC responsible for any other promotional firm, its program or its structure.